Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/39596
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorArroyave Ospina, Johanna Carolina-
dc.contributor.authorBuist Homan, Manon-
dc.contributor.authorSchmidt, Martina-
dc.contributor.authorMoshage, Han-
dc.date.accessioned2024-06-03T19:42:32Z-
dc.date.available2024-06-03T19:42:32Z-
dc.date.issued2023-
dc.identifier.citationArroyave-Ospina JC, Buist-Homan M, Schmidt M, Moshage H. Protective effects of caffeine against palmitate-induced lipid toxicity in primary rat hepatocytes is associated with modulation of adenosine receptor A1 signaling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 Sept;165:114884. Epub 2023 Jul 7. doi: 10.1016/j.biopha.2023.114884spa
dc.identifier.issn0753-3322-
dc.identifier.urihttps://hdl.handle.net/10495/39596-
dc.description.abstractABSTRACT: Background: Epidemiological evidence has shown an association between coffee consumption and reduced risk for chronic liver diseases, including metabolic-dysfunction-associated liver disease (MALFD). Lipotoxicity is a key cause of hepatocyte injury during MAFLD. The coffee component caffeine is known to modulate adenosine receptor signaling via the antagonism of adenosine receptors. The involvement of these receptors in the prevention of hepatic lipotoxicity has not yet been explored. The aim of this study was to explore whether caffeine protects against palmitate-induced lipotoxicity by modulating adenosine receptor signaling. Methods: Primary hepatocytes were isolated from male rats. Hepatocytes were treated with palmitate with or without caffeine or 1,7DMX. Lipotoxicity was verified using Sytox viability staining and mitochondrial JC-10 staining. PKA activation was verified by Western blotting. Selective (ant)agonists of A1AR (DPCPX and CPA, respectively) and A2AR (istradefyline and regadenoson, respectively), the AMPK inhibitor compound C, and the Protein Kinase A (PKA) inhibitor Rp8CTP were used. Lipid accumulation was verified by ORO and BODIPY 453/50 staining. Results: Caffeine and its metabolite 1,7DMX prevented palmitate-induced toxicity in hepatocytes. The A1AR antagonist DPCPX also prevented lipotoxicity, whereas both the inhibition of PKA and the A1AR agonist CPA (partially) abolished the protective effect. Caffeine and DPCPX increased lipid droplet formation only in palmitate-treated hepatocytes and decreased mitochondrial ROS production. Conclusions: The protective effect of caffeine against palmitate lipotoxicity was shown to be dependent on A1AR receptor and PKA activation. Antagonism of A1AR also protects against lipotoxicity. Targeting A1AR receptor may be a potential therapeutic intervention with which to treat MAFLD. Keywords: Adenosine receptor A1; Adenosine receptors; Caffeine; Lipotoxicity; MAFLD; PKA.spa
dc.format.extent16 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherElsevierspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleProtective effects of caffeine against palmitate-induced lipid toxicity in primary rat hepatocytes is associated with modulation of adenosine receptor A1 signalingspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGrupo de Gastrohepatologíaspa
dc.identifier.doi10.1016/j.biopha.2023.114884-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1950-6007-
oaire.citationtitleBiomedicine and Pharmacotherapyspa
oaire.citationstartpage1spa
oaire.citationendpage16spa
oaire.citationvolume165spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by-nc-nd/4.0/spa
oaire.fundernameColombia. Ministerio de Ciencia, Tecnología e Innovación - Mincienciasspa
dc.publisher.placeParís, Franciaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsCafeína-
dc.subject.decsCaffeine-
dc.subject.decsFarmacología-
dc.subject.decsPharmacology-
dc.subject.decsHepatocitos-
dc.subject.decsHepatocytes-
dc.subject.decsPalmitatos-
dc.subject.decsPalmitates-
dc.subject.decsReceptor de Adenosina A1-
dc.subject.decsReceptor, Adenosine A1-
dc.subject.decsMetabolismo-
dc.subject.decsMetabolism-
dc.description.researchgroupidCOL0024159spa
oaire.awardnumber783–2017spa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D002110-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D010600-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D022781-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D010168-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D043682-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D008660-
dc.relation.ispartofjournalabbrevBiomed. Pharmacother.spa
oaire.funderidentifier.rorRoR:03fd5ne08-
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
ArroyaveJohanna_2023_Caffeine_hepatocytes_receptorA1.pdfArtículo de investigación5.74 MBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons